RA, Forbion and Sanofi Ventures appear to back new eye drug from Korea
The trend continues in which big-name venture investors band together to back new companies with an experimental medicine developed by another biotech. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
The trend continues in which big-name venture investors band together to back new companies with an experimental medicine developed by another biotech.
RA Capital and Forbion — partners on a couple biotech launches in recent quarters — ...
Source: Endpoints News